|
|
|
Hypertension Clinical Trials |
|
Thank you for your interest in clinical trials for Hypertension
Please click "Search" to find Hypertension clinical trials and medical research studies.
If you receive too many study listings you may enter your zip code to find the locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
|
|
Your search returned 15 studies:
|
|
|
|
|
Results from other databases:
|
|
Your search returned over 250 results. The top 250 results are being displayed. Please use
additional keywords or decrease the search distance. |
|
Your search returned 250 studies:
- 3-D Transcranial Ultrasound Analysis Study - NCT00239525-27710
Conditions: Cerebrovascular Accident, Intracranial Hypertension
Location: Durham, NC
- A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers - NCT01172496-78744
Conditions: Pulmonary Arterial Hypertension
Location: Austin, TX
- A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis - NCT01042158-21287
Conditions: Pulmonary Arterial Hypertension - Systemic Sclerosis - Scleroderma Spectrum of Diseases - Connective Tissue Disease - Pulmonary Hypertension
Location: Baltimore, MD
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-02139
Conditions: Hypertension - Asthma
Location: Cambridge, MA
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-06105
Conditions: Hypertension - Asthma
Location: Hartford, CT
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-14260
Conditions: Hypertension - Asthma
Location: Buffalo, NY
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-15213
Conditions: Hypertension - Asthma
Location: Pittsburgh, PA
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-27157
Conditions: Hypertension - Asthma
Location: Winston-Salem, NC
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-27559
Conditions: Hypertension - Asthma
Location: Chapel Hill, NC
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-27705
Conditions: Hypertension - Asthma
Location: Durham, NC
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-29303
Conditions: Hypertension - Asthma
Location: Spartanburg, SC
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-29425
Conditions: Hypertension - Asthma
Location: Charleston, SC
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-32601
Conditions: Hypertension - Asthma
Location: Gainesville, FL
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-33612
Conditions: Hypertension - Asthma
Location: Tampa, FL
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-50314
Conditions: Hypertension - Asthma
Location: Des Moines, IA
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-50702
Conditions: Hypertension - Asthma
Location: Waterloo, IA
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-52242
Conditions: Hypertension - Asthma
Location: Iowa City, IA
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-52803
Conditions: Hypertension - Asthma
Location: Davenport, IA
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-53210
Conditions: Hypertension - Asthma
Location: Milwaukee, WI
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-53715
Conditions: Hypertension - Asthma
Location: Madison, WI
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-77030
Conditions: Hypertension - Asthma
Location: Houston, TX
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-78229
Conditions: Hypertension - Asthma
Location: San Antonio, TX
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-78701
Conditions: Hypertension - Asthma
Location: Austin, TX
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-79106
Conditions: Hypertension - Asthma
Location: Amarillo, TX
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-79968
Conditions: Hypertension - Asthma
Location: El Paso, TX
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-83209
Conditions: Hypertension - Asthma
Location: Pocatello, ID
- A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities - NCT00935077-92093
Conditions: Hypertension - Asthma
Location: San Diego, CA
- A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension - NCT01104870-90024
Conditions: Pulmonary Hypertension
Location: Los Angeles, CA
- A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma - NCT01123785-
Conditions: Glaucoma - Ocular Hypertension
Location: New York, NY
- A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma - NCT01123785-27262
Conditions: Glaucoma - Ocular Hypertension
Location: High Point, NC
- A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma - NCT01123785-91205
Conditions: Glaucoma - Ocular Hypertension
Location: Glendale, CA
- A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure - NCT01005290-
Conditions: Hypertension
Location: New York, NY
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-90013
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Los Angeles, CA
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-90025
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Los Angeles, CA
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-90057
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Los Angeles, CA
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-90247
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Gardena, CA
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-90505
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Torrance, CA
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-90630
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Cypress, CA
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-90806
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Long Beach, CA
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-91105
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Pasadena, CA
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-92663
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Newport Beach, CA
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-92844
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Location: Garden Grove, CA
- A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension - NCT00850369-27710
Conditions: Pulmonary Hypertension - Sickle Cell Disease
Location: Durham, NC
- A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome - NCT00940966-25302
Conditions: Elevated Triglycerides - Systolic Hypertension - Insulin Resistance - Abdominal Obesity
Location: Charleston, WV
- A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension - NCT00853112-15212
Conditions: Hypertension, Pulmonary
Location: Pittsburgh, PA
- A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension - NCT00853112-32610
Conditions: Hypertension, Pulmonary
Location: Gainesville, FL
- A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension - NCT00853112-68131
Conditions: Hypertension, Pulmonary
Location: Omaha, NE
- A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension - NCT00853112-75390
Conditions: Hypertension, Pulmonary
Location: Dallas, TX
- A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension - NCT00853112-85006
Conditions: Hypertension, Pulmonary
Location: Phoenix, AZ
- A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension - NCT00853112-85020
Conditions: Hypertension, Pulmonary
Location: Phoenix, AZ
- A Study in the Use of Home Blood Pressure Monitoring and Telephone Follow-up to Control Blood Pressure - NCT00662753-20018
Conditions: Hypertension
Location: Washington, DC
- A Study in the Use of Home Blood Pressure Monitoring and Telephone Follow-up to Control Blood Pressure - NCT00662753-20032
Conditions: Hypertension
Location: Washington, DC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-14224
Conditions: Type 2 Diabetes
Location: West Seneca, NY
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-15216
Conditions: Type 2 Diabetes
Location: Pittsburgh, PA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-23454
Conditions: Type 2 Diabetes
Location: Virginia Beach, VA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-27408
Conditions: Type 2 Diabetes
Location: Greensboro, NC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-28209
Conditions: Type 2 Diabetes
Location: Charlotte, NC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-28262
Conditions: Type 2 Diabetes
Location: Charlotte, NC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29485
Conditions: Type 2 Diabetes
Location: Summerville, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29582
Conditions: Type 2 Diabetes
Location: North Myrtle Beach, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29605
Conditions: Type 2 Diabetes
Location: Greenville, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29621
Conditions: Type 2 Diabetes
Location: Anderson, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29687
Conditions: Type 2 Diabetes
Location: Taylors, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-30328
Conditions: Type 2 Diabetes
Location: Sandy Springs, GA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-31069
Conditions: Type 2 Diabetes
Location: Perry, GA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-32428
Conditions: Type 2 Diabetes
Location: Chipley, FL
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-33140
Conditions: Type 2 Diabetes
Location: Miami Beach, FL
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-33313
Conditions: Type 2 Diabetes
Location: Lauderdale Lakes, FL
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-33472
Conditions: Type 2 Diabetes
Location: Boynton Beach, FL
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-34652
Conditions: Type 2 Diabetes
Location: New Port Richey, FL
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-35215
Conditions: Type 2 Diabetes
Location: Birmingham, AL
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-35565
Conditions: Type 2 Diabetes
Location: Haleyville, AL
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-36360
Conditions: Type 2 Diabetes
Location: Ozark, AL
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-37404
Conditions: Type 2 Diabetes
Location: Chattanooga, TN
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-37620
Conditions: Type 2 Diabetes
Location: Bristol, TN
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-37660
Conditions: Type 2 Diabetes
Location: Kingsport, TN
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-38017
Conditions: Type 2 Diabetes
Location: Collierville, TN
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-38119
Conditions: Type 2 Diabetes
Location: Memphis, TN
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-38138
Conditions: Type 2 Diabetes
Location: Germantown, TN
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-39159
Conditions: Type 2 Diabetes
Location: Rolling Fork, MS
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-39209
Conditions: Type 2 Diabetes
Location: Jackson, MS
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-42431
Conditions: Type 2 Diabetes
Location: Madisonville, KY
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-43551
Conditions: Type 2 Diabetes
Location: Perrysburg, OH
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-44614
Conditions: Type 2 Diabetes
Location: Canal Fulton, OH
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-44718
Conditions: Type 2 Diabetes
Location: Canton, OH
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-45429
Conditions: Type 2 Diabetes
Location: Kettering, OH
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-45631
Conditions: Type 2 Diabetes
Location: Gallipolis, OH
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-46250
Conditions: Type 2 Diabetes
Location: Indianapolis, IN
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-60607
Conditions: Type 2 Diabetes
Location: Chicago, IL
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-70458
Conditions: Type 2 Diabetes
Location: Slidell, LA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-73099
Conditions: Type 2 Diabetes
Location: Yukon, OK
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-77024
Conditions: Type 2 Diabetes
Location: Houston, TX
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-77081
Conditions: Type 2 Diabetes
Location: Houston, TX
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-78130
Conditions: Type 2 Diabetes
Location: New Braunfels, TX
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-78224
Conditions: Type 2 Diabetes
Location: San Antonio, TX
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-78229
Conditions: Type 2 Diabetes
Location: San Antonio, TX
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-80012
Conditions: Type 2 Diabetes
Location: Aurora, CO
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-80209
Conditions: Type 2 Diabetes
Location: Denver, CO
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-83686
Conditions: Type 2 Diabetes
Location: Nampa, ID
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-83704
Conditions: Type 2 Diabetes
Location: Boise, ID
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-84010
Conditions: Type 2 Diabetes
Location: Bountiful, UT
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-84088
Conditions: Type 2 Diabetes
Location: West Jordan, UT
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-85020
Conditions: Type 2 Diabetes
Location: Phoenix, AZ
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-85203
Conditions: Type 2 Diabetes
Location: Mesa, AZ
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-85213
Conditions: Type 2 Diabetes
Location: Mesa, AZ
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-90255
Conditions: Type 2 Diabetes
Location: Huntington Park, CA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-90404
Conditions: Type 2 Diabetes
Location: Santa Monica, CA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-91325
Conditions: Type 2 Diabetes
Location: Northridge, CA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-92708
Conditions: Type 2 Diabetes
Location: Fountain Valley, CA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-92780
Conditions: Type 2 Diabetes
Location: Tustin, CA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-92801
Conditions: Type 2 Diabetes
Location: Anaheim, CA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-95032
Conditions: Type 2 Diabetes
Location: Los Gatos, CA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-95204
Conditions: Type 2 Diabetes
Location: Stockton, CA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-97404
Conditions: Type 2 Diabetes
Location: Eugene, OR
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-01608
Conditions: Hypertension, Pulmonary
Location: Worcester, MA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-02111
Conditions: Hypertension, Pulmonary
Location: Boston, MA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-02115
Conditions: Hypertension, Pulmonary
Location: Boston, MA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-02118
Conditions: Hypertension, Pulmonary
Location: Boston, MA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-02903
Conditions: Hypertension, Pulmonary
Location: Providence, RI
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-04102
Conditions: Hypertension, Pulmonary
Location: Portland, ME
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-07112
Conditions: Hypertension, Pulmonary
Location: Newark, NJ
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-07962
Conditions: Hypertension, Pulmonary
Location: Morristown, NJ
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-10003
Conditions: Hypertension, Pulmonary
Location: New York, NY
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-10019
Conditions: Hypertension, Pulmonary
Location: New York, NY
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-10021
Conditions: Hypertension, Pulmonary
Location: New York, NY
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-10032
Conditions: Hypertension, Pulmonary
Location: New York, NY
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-11040
Conditions: Hypertension, Pulmonary
Location: New Hyde Park, NY
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-14623
Conditions: Hypertension, Pulmonary
Location: Rochester, NY
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-15212
Conditions: Hypertension, Pulmonary
Location: Pittsburgh, PA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-15213
Conditions: Hypertension, Pulmonary
Location: Pittsburgh, PA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-19104
Conditions: Hypertension, Pulmonary
Location: Philadelphia, PA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-21201
Conditions: Hypertension, Pulmonary
Location: Baltimore, MD
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-22908
Conditions: Hypertension, Pulmonary
Location: Charlottesville, VA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-23298
Conditions: Hypertension, Pulmonary
Location: Richmond, VA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-23507
Conditions: Hypertension, Pulmonary
Location: Norfolk, VA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-27599
Conditions: Hypertension, Pulmonary
Location: Chapel Hill, NC
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-30030
Conditions: Hypertension, Pulmonary
Location: Decatur, GA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-30322
Conditions: Hypertension, Pulmonary
Location: Atlanta, GA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-32610
Conditions: Hypertension, Pulmonary
Location: Gainesvillle, FL
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-32803
Conditions: Hypertension, Pulmonary
Location: Orlando, FL
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-33331
Conditions: Hypertension, Pulmonary
Location: Weston, FL
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-34741
Conditions: Hypertension, Pulmonary
Location: Kissimmee, FL
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-35294
Conditions: Hypertension, Pulmonary
Location: Birmingham, AL
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-36617
Conditions: Hypertension, Pulmonary
Location: Mobile, AL
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-37232
Conditions: Hypertension, Pulmonary
Location: Nashville, TN
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-43221
Conditions: Hypertension, Pulmonary
Location: Columbus, OH
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-44106
Conditions: Hypertension, Pulmonary
Location: Cleveland, OH
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-44195
Conditions: Hypertension, Pulmonary
Location: Cleveland, OH
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-45219
Conditions: Hypertension, Pulmonary
Location: Cincinnati, OH
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-45267
Conditions: Hypertension, Pulmonary
Location: Cincinnati, OH
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-48109
Conditions: Hypertension, Pulmonary
Location: Ann Arbor, MI
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-48201
Conditions: Hypertension, Pulmonary
Location: Detroit, MI
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-52242
Conditions: Hypertension, Pulmonary
Location: Iowa City, IA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-53215
Conditions: Hypertension, Pulmonary
Location: Milwaukee, WI
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-55905
Conditions: Hypertension, Pulmonary
Location: Rochester, MN
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-60181
Conditions: Hypertension, Pulmonary
Location: Oakbrook Terrace, IL
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-60612
Conditions: Hypertension, Pulmonary
Location: Chicago, IL
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-63110
Conditions: Hypertension, Pulmonary
Location: St. Louis, MO
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-70112
Conditions: Hypertension, Pulmonary
Location: New Orleans, LA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-75390
Conditions: Hypertension, Pulmonary
Location: Dallas, TX
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-76508
Conditions: Hypertension, Pulmonary
Location: Temple, TX
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-77030
Conditions: Hypertension, Pulmonary
Location: Houston, TX
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-80045
Conditions: Hypertension, Pulmonary
Location: Aurora, CO
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-84157
Conditions: Hypertension, Pulmonary
Location: Murray, UT
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-85006
Conditions: Hypertension, Pulmonary
Location: Phoenix, AZ
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-85013
Conditions: Hypertension, Pulmonary
Location: Phoenix, AZ
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-90073
Conditions: Hypertension, Pulmonary
Location: Los Angeles, CA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-90502
Conditions: Hypertension, Pulmonary
Location: Torrance, CA
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) - NCT01178073-92037
Conditions: Hypertension, Pulmonary
Location: La Jolla, CA
- A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives - NCT00825188-39216
Conditions: Obesity - Hypertension
Location: Jackson, MS
- A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension - NCT01028651-53792
Conditions: Portopulmonary Hypertension - Pulmonary Arterial Hypertension - Pulmonary Hypertension
Location: Madison, WI
- A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension - NCT01028651-90024
Conditions: Portopulmonary Hypertension - Pulmonary Arterial Hypertension - Pulmonary Hypertension
Location: Los Angeles, CA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-15212
Conditions: Pulmonary Hypertension
Location: Pittsburgh, PA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-21205
Conditions: Pulmonary Hypertension
Location: Baltimore, MD
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-30030
Conditions: Pulmonary Hypertension
Location: Decatur, GA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-30342
Conditions: Pulmonary Hypertension
Location: Atlanta, GA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-33136
Conditions: Pulmonary Hypertension
Location: Miami, FL
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-35233
Conditions: Pulmonary Hypertension
Location: Birmingham, AL
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-43221
Conditions: Pulmonary Hypertension
Location: Columbus, OH
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-44195
Conditions: Pulmonary Hypertension
Location: Cleveland, OH
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-45014
Conditions: Pulmonary Hypertension
Location: Fairfield, OH
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-75390
Conditions: Pulmonary Hypertension
Location: Dallas, TX
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-80045
Conditions: Pulmonary Hypertension
Location: Aurora, CO
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-92093
Conditions: Pulmonary Hypertension
Location: La Jolla, CA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. - NCT00855465-95817
Conditions: Pulmonary Hypertension
Location: Sacramento, CA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-02111
Conditions: Pulmonary Hypertension
Location: Boston, MA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-02115
Conditions: Pulmonary Hypertension
Location: Boston, MA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-04102
Conditions: Pulmonary Hypertension
Location: Portland, ME
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-15212
Conditions: Pulmonary Hypertension
Location: Pittsburgh, PA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-21205
Conditions: Pulmonary Hypertension
Location: Baltimore, MD
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-30030
Conditions: Pulmonary Hypertension
Location: Decatur, GA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-30342
Conditions: Pulmonary Hypertension
Location: Atlanta, GA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-33136
Conditions: Pulmonary Hypertension
Location: Miami, FL
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-35233
Conditions: Pulmonary Hypertension
Location: Birmingham, AL
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-43221
Conditions: Pulmonary Hypertension
Location: Columbus, OH
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-44195
Conditions: Pulmonary Hypertension
Location: Cleveland, OH
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-45014
Conditions: Pulmonary Hypertension
Location: Fairfield, OH
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-55902
Conditions: Pulmonary Hypertension
Location: Rochester, MN
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-75390
Conditions: Pulmonary Hypertension
Location: Dallas, TX
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-80045
Conditions: Pulmonary Hypertension
Location: Aurora, CO
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-90073
Conditions: Pulmonary Hypertension
Location: Los Angeles, CA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-90502
Conditions: Pulmonary Hypertension
Location: Torrance, CA
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) - NCT00810693-95817
Conditions: Pulmonary Hypertension
Location: Sacramento, CA
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-02114
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Boston, MA
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-15212
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Pittsburgh, PA
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-15213
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Pittsburgh, PA
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-21205
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Baltimore, MD
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-22042
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Falls Church, VA
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-33136
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Miami, FL
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-44106
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Cleveland, OH
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-45014
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Fairfield, OH
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-55905
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Rochester, MN
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-63110
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: St. Louis, MO
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-80045
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Aurora, CO
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-90502
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Torrance, CA
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-92103
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: San Diego, CA
- A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction - NCT01065454-95817
Conditions: Hypertension, Pulmonary - Ventricular Dysfunction, Left
Location: Sacramento, CA
- Acupuncture and Laser Acupoint Treatment on Hypertension - NCT00459680-63017
Conditions: Hypertension
Location: Chesterfield, MO
- ADMA Levels in End-Stage Renal Disease - NCT00350974-48109
Conditions: Chronic Kidney Disease - Hypertension
Location: Ann Arbor, MI
- Aerobic Exercise in Patients With Pulmonary Hypertension - NCT00678821-20892
Conditions: Hypertension, Pulmonary
Location: Bethesda, MD
- Aerobic Exercise in Patients With Pulmonary Hypertension - NCT00678821-22042
Conditions: Hypertension, Pulmonary
Location: Falls Church, VA
- Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension - NCT00980031-68131
Conditions: Myocardial Remodeling
Location: Omaha, NE
- Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension - NCT00942994-02126
Conditions: Hypertension
Location: Mattapan, MA
- Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension - NCT00942994-20110
Conditions: Hypertension
Location: Manassas, VA
- Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension - NCT00942994-33143
Conditions: Hypertension
Location: South Miami, FL
- Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension - NCT00942994-72201
Conditions: Hypertension
Location: Little Rock, AR
- Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension - NCT00942994-98133
Conditions: Hypertension
Location: Seattle, WA
- Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide - NCT00356265-48109
Conditions: Chronic Kidney Disease - Hypertension
Location: Ann Arbor, MI
- Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension - NCT00851929-
Conditions: Sarcoidosis - Pulmonary Hypertension
Location: Chapel Hill, NC
- Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension - NCT00851929-29466
Conditions: Sarcoidosis - Pulmonary Hypertension
Location: Charleston, SC
- Ambulatory Blood Pressure Monitoring in Hypertension - NCT00166634-40202
Conditions: Hypertension
Location: Louisville, KY
- Ambulatory Blood Pressure Monitoring in Hypertension - NCT00166634-44106
Conditions: Hypertension
Location: Cleveland, OH
- Ambulatory Blood Pressure Monitoring in Hypertension - NCT00166634-72202
Conditions: Hypertension
Location: Little Rock, AR
- Ambulatory Blood Pressure Monitoring in Hypertension - NCT00166634-84132
Conditions: Hypertension
Location: Salt Lake City, UT
- An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects - NCT00811564-
Conditions: Glaucoma - Ocular Hypertension
Location: Slingerlands, NY
- An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age - NCT01151410-
Conditions: Hypertension
Location: Louisville, KY
- An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension - NCT01037920-80204
Conditions: Hypertension
Location: Denver, CO
- Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease - NCT01036802-27599
Conditions: Pulmonary Hypertension
Location: Chapel Hill, NC
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: Miami, FL
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-02111
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: Boston, MA
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-02118
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: Boston, MA
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-03756
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: Lebanon, NH
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-10029
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: New York, NY
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-10032
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: New York, NY
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-11040
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: New Hyde Park, NY
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-11501
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: Mineola, NY
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-12208
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: Albany, NY
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-12512
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: Pittsburgh, PA
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-15213
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: Pittsburgh, PA
- ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis - NCT00879229-19104
Conditions: Idiopathic Pulmonary Fibrosis - Pulmonary Hypertension
Location: Philadelphia, PA
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|